Allogeneic Cell Therapy: What Options Do Sponsors Have To Scale Their Product?

As the allogeneic cell therapy industry moves beyond proof of principle experimentation and toward more human clinical trials, sponsors have a mighty challenge ahead of them - growing more cells. For example, a single patient dose of mesenchymal stem cell therapy could require hundreds of millions of cells or more. Because the cells themselves are the product, and that product, following downstream processing, goes to entire populations of patients, finding a way to scale up cell cultures while preserving underlying biology is essential.

Explore Corning Life Science's automated scale-up solutions and how they can help your organization creating a sustainable seed chain.